These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34377887)

  • 1. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report.
    Warren BB; Chan A; Manco-Johnson M; Branchford BR; Buckner TW; Moyer G; Gibson E; Thornhill D; Wang M; Ng CJ
    Res Pract Thromb Haemost; 2021 Jul; 5(5):e12571. PubMed ID: 34377887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.
    Pipe SW; Trzaskoma B; Minhas M; Lehle M; Ko RH; Gao L; Mahlangu J; Kempton CL; Kessler CM; Kruse-Jarres R
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100077. PubMed ID: 36908770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
    Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X
    Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
    Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
    J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis.
    Garcia J; Hammer MR; Zia A
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102238. PubMed ID: 38053983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.
    Jonsson F; Schmitt C; Petry C; Mercier F; Frey N; Retout S
    Clin Pharmacokinet; 2021 Jul; 60(7):931-941. PubMed ID: 33709296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.
    Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR
    EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
    Tiede A; Hart C; Knöbl P; Greil R; Oldenburg J; Sachs UJ; Miesbach W; Pfrepper C; Trautmann-Grill K; Holstein K; Pilch J; Möhnle P; Schindler C; Weigt C; Schipp D; May M; Dobbelstein C; Pelzer FJ; Werwitzke S; Klamroth R
    Lancet Haematol; 2023 Nov; 10(11):e913-e921. PubMed ID: 37858328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab.
    Levy-Mendelovich S; Brutman-Barazani T; Budnik I; Avishai E; Barg AA; Levy T; Misgav M; Livnat T; Kenet G
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review.
    Young G; Pipe SW; Kenet G; Oldenburg J; Safavi M; Czirok T; Nissen F; Mahlangu J
    Res Pract Thromb Haemost; 2024 May; 8(4):102415. PubMed ID: 38812987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia A: Emicizumab monitoring and impact on coagulation testing.
    Nardi MA
    Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
    Ebbert PT; Xavier F; Seaman CD; Ragni MV
    Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review.
    Hassan E; Motwani J
    Pediatr Hematol Oncol; 2022 Aug; 39(5):418-426. PubMed ID: 35170384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
    Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
    Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.